<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03297424</url>
  </required_header>
  <id_info>
    <org_study_id>PLX124-01</org_study_id>
    <nct_id>NCT03297424</nct_id>
  </id_info>
  <brief_title>A Study of PLX2853 in Advanced Malignancies.</brief_title>
  <official_title>A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Plexxikon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Plexxikon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics&#xD;
      and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced&#xD;
      malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.</measure>
    <time_frame>First dose of study drug through at least 30 days after end of treatment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC) of PLX2853.</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) of PLX2853.</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to peak concentration (Tmax) of PLX2853.</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life (t1/2) of PLX2853.</measure>
    <time_frame>From first dose of PLX2853 up to 30 days after end of treatment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experience dose limiting toxicity as defined in the protocol.</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The highest dose level at which less than 2 of 6 participants or less than 33% of participants (if cohort is expanded beyond 6) experience a dose limiting toxicity will be considered the maximum tolerated dose / recommended phase 2 dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in disease burden using RECIST 1.1 (solid tumors) or Lugano criteria (NHL).</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) defined according to standard criteria for the relevant malignancy [Phase1b]</measure>
    <time_frame>From the first dose of study drug until the date of documented response to treatment, assessed up to 2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>DOR defined as the time from the initial objective response to disease progression or death, whichever occurs first, assessed up to 2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>PFS time is defined as the time from the first dose of PLX2853 to disease progression or death, whichever occurs first, assessed up to 2 years.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the first dose of study drug until the date of death from any cause, assessed up to 2 years.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <condition>Uveal Melanoma</condition>
  <condition>Ovarian Clear Cell Carcinoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Advanced Malignancies</condition>
  <condition>Solid Tumor</condition>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>PLX2853</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b (Dose Escalation): Approximately 45 subjects with advanced malignancies to establish the MTD/RP2D. Up to 6 additional subjects may be enrolled at the MTD/RP2D as a dose confirmation.&#xD;
Phase 2a (Dose Expansion): There will be 5 total expansion cohorts. Either 10 or 29 subjects per cohort in each of 4 expansion cohorts: advanced SCLC, uveal melanoma, OCCC, and any other advanced malignancy with a known ARID1A mutation (between 40 to 116 subjects total for the solid tumor expansion phase). For the 5th expansion cohort, up to 20 subjects may be enrolled for NHL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLX2853</intervention_name>
    <description>tablets</description>
    <arm_group_label>PLX2853</arm_group_label>
    <other_name>PLX2853 tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of one of the following:&#xD;
&#xD;
          -  Phase 1b:&#xD;
&#xD;
               -  Histologically confirmed advanced refractory solid tumor that is measurable or&#xD;
                  evaluable per RECIST 1.1 criteria.&#xD;
&#xD;
               -  Histologically confirmed NHL: diffuse large B-cell lymphoma and follicular&#xD;
                  lymphoma (Grade 1-3A) which is measurable or evaluable per Lugano criteria, has&#xD;
                  progressed following at least 1 line of prior anticancer therapy.&#xD;
&#xD;
          -  Phase 2a: Patients with various solid tumors or NHL who have received prior therapy.&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1&#xD;
&#xD;
          -  Adequate organ function as appropriate for the disease under study. All screening&#xD;
             laboratory tests should be performed within 10 days of treatment initiation.&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test at&#xD;
             Screening (≤7 days prior to 1st study drug dose) and must agree to use an effective&#xD;
             form of contraception from the time of the negative pregnancy test up to 90 days after&#xD;
             the last dose of study drug. Effective forms of contraception include abstinence,&#xD;
             hormonal contraceptive in conjunction with a barrier method, or a double barrier&#xD;
             method. Women of non-child-bearing potential may be included if they are either&#xD;
             surgically sterile or have been postmenopausal for ≥1 year.&#xD;
&#xD;
          -  Fertile men must agree to use an effective method of birth control during the study&#xD;
             and for up to 90 days after the last dose of study drug.&#xD;
&#xD;
          -  All associated clinically significant drug-related toxicity from previous cancer&#xD;
             therapy must be resolved prior to study treatment administration (alopecia, erectile&#xD;
             impotence, hot flashes, decreased libido, and neuropathy is allowed).&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent prior to any study-related&#xD;
             procedures and to comply with all study requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to a bromodomain inhibitor, such as OTX-015 or CPI-0610&#xD;
&#xD;
          -  Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade 2&#xD;
&#xD;
          -  Autoimmune hemolytic anemia or autoimmune thrombocytopenia&#xD;
&#xD;
          -  Presence of symptomatic or uncontrolled central nervous system or leptomeningeal&#xD;
             metastases&#xD;
&#xD;
          -  Known or suspected allergy to the investigational agent or any agent given in&#xD;
             association with this trial&#xD;
&#xD;
          -  Clinically significant cardiac disease such as cardiac arrhythmias including&#xD;
             bradyarrhythmias and/or subjects who require anti-arrhythmic therapy (excluding beta&#xD;
             blockers or digoxin), including uncontrolled hypertension or arterial or venous&#xD;
             thrombotic events. Subjects with controlled atrial fibrillation are not excluded.&#xD;
&#xD;
          -  Inability to take oral medication or significant nausea and vomiting, malabsorption,&#xD;
             or significant small bowel resection that, in the opinion of the Investigator, would&#xD;
             preclude adequate absorption&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Subject has known human immunodeficiency virus (HIV), hepatitis B or hepatitis C&#xD;
             infection or is known to be a carrier of hepatitis B or C. Subjects who are positive&#xD;
             for hepatitis C virus (HCV) antibody must be negative for HCV by polymerase chain&#xD;
             reaction (PCR) to be eligible. Subjects with occult or prior hepatitis B virus (HBV)&#xD;
             infection (defined as positive total hepatitis B core antibody (HBcAb) and negative&#xD;
             hepatitis B surface antigen (HBsAg) may be included if HBV DNA is undetectable. These&#xD;
             subjects must be willing to undergo additional testing per local standard of care.&#xD;
&#xD;
          -  Active second malignancy with the exception of any of the following:&#xD;
&#xD;
               -  Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or&#xD;
                  in situ cervical cancer;&#xD;
&#xD;
               -  Adequately treated Stage I cancer from which the subject is currently in&#xD;
                  remission and has been in remission for ≥2 years;&#xD;
&#xD;
               -  Low-risk prostate cancer with Gleason score &lt;7 and prostate-specific antigen &lt;10&#xD;
                  ng/mL; or&#xD;
&#xD;
               -  Any other cancer from which the patient has been disease-free for ≥3 years.&#xD;
&#xD;
          -  Subjects with documented hepatic metastases involving &gt;50% of the hepatic parenchyma,&#xD;
             or any individual liver metastasis &gt;5 cm, as assessed by the investigator.&#xD;
&#xD;
          -  Major surgery or significant traumatic injury within 14 days prior to Cycle 1 Day 1&#xD;
&#xD;
          -  Receipt of anti-cancer therapy with insufficient washout prior to Cycle 1 Day 1: No&#xD;
             chemotherapy, radiation therapy, or small molecule tyrosine kinase inhibitors (TKI)&#xD;
             for the treatment of cancer within 14 days or 5 half-lives (whichever is shorter) of&#xD;
             Cycle 1 Day 1. Certain standard of care hormonal anticancer therapies, such as agents&#xD;
             targeted to GnRH for the treatment of prostate cancer or aromatase inhibitors for the&#xD;
             treatment of breast cancer, may be permitted after consultation with the medical&#xD;
             monitor. No immune therapy or other biologic therapy (other monoclonal antibodies or&#xD;
             antibody-drug conjugates [ADCs]) for the treatment of cancer within 28 days of Cycle 1&#xD;
             Day 1.&#xD;
&#xD;
          -  Subject is receiving systemic steroids at doses greater than the equivalent of&#xD;
             prednisone 10 mg daily, with the exception of intermittent use for the treatment of&#xD;
             emesis&#xD;
&#xD;
          -  Subject is participating in any other therapeutic clinical study (observational or&#xD;
             registry trials are allowed)&#xD;
&#xD;
          -  Female subjects who are pregnant or breast-feeding&#xD;
&#xD;
          -  Presence of any other medical, psychological, familial, sociological, or geographic&#xD;
             condition potentially hampering compliance with the study protocol or would interfere&#xD;
             with the study endpoints or the subject's ability to participate in the study in the&#xD;
             judgement of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kerry Inokuchi</last_name>
    <phone>510-647-4148</phone>
    <email>kinokuchi@plexxikon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Watkins</last_name>
    <phone>510-647-4151</phone>
    <email>Pwatkins@plexxikon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia Aguilera</last_name>
      <phone>623-238-7667</phone>
      <email>leaguilera@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center / University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harshita Gahankari</last_name>
      <phone>305-243-3379</phone>
      <email>harshita.gahankari@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Vann</last_name>
      <phone>212-305-3432</phone>
      <email>ev2480@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics (START)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Amaya</last_name>
      <email>alexamaya@startsa.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Spira, MD</last_name>
      <email>Alexander.Spira@USOncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 8, 2017</study_first_submitted>
  <study_first_submitted_qc>September 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2017</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PLX2853</keyword>
  <keyword>Small cell lung cancer (SCLC)</keyword>
  <keyword>Uveal Melanoma</keyword>
  <keyword>Ovarian Clear Cell Carcinoma</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>Advanced Malignancies</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Diffuse Large B Cell Lymphoma (DLBCL)</keyword>
  <keyword>Follicular Lymphoma (FL)</keyword>
  <keyword>ARID1A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Adenomyoepithelioma</mesh_term>
    <mesh_term>Adenocarcinoma, Clear Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

